Trial reportEuropean heart journal2022
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
Trial report in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2023Pooled it
- Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction-a prespecified analysis of REVIVED-BCIS2.European heart journal. Quality of care & clinical outcomes · 2025Trial
- Characteristics and Outcomes of Older Patients Undergoing Protected Percutaneous Coronary Intervention With Impella.Journal of the American Heart Association · 2025Trial
- Impact of Coronary Endarterectomy on Mid-Term Left Ventricular Functional Recovery in Diffuse Coronary Artery Disease.Reviews in cardiovascular medicine · 2026Article
- Association of Serum Calprotectin and the C-Reactive Protein-Triglyceride-Glucose Index with SYNTAX Score in Patients with Newly Diagnosed Coronary Artery Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Chronic Total Occlusion Percutaneous Coronary Intervention: A Consensus of the National Heart Center in Collaboration With the Saudi CTO Club of the Saudi Arabian Cardiac Interventional Society.Saudi medical journal · 2026Article
- The Equity Deficit in Revascularization Research: Patient Perspectives Emphasize the Need for Inclusive, Patient-Centered Outcomes.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Risk factors for cardiac death in women with coronary artery disease.European heart journal open · 2026Article
- Article
- Advances in Technology and Technique in Percutaneous Coronary Intervention: A Clinical Review.Internal medicine (Tokyo, Japan) · 2026Review
- Impact of Periprocedural Risk Predictors on Long-Term Outcomes in Patients with Diabetes Undergoing Coronary Artery Bypass Grafting.Medicina (Kaunas, Lithuania) · 2025Article
- Contemporary Percutaneous Coronary Intervention in Diabetic Patients.Reviews in cardiovascular medicine · 2025Review
- Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Analysis of the Predictive Effect of Cardiac Color Doppler Ultrasound Combined With Carotid Ultrasound on Major Adverse Cardiac Events Following Percutaneous Coronary Intervention.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- Chronic Total Occlusions: Current Approaches, Evidence and Outcomes.Journal of clinical medicine · 2025Review
- Risk Factors for Coronary Events After Robotic Hybrid Off-Pump Coronary Revascularization.Journal of cardiovascular development and disease · 2025Article
- A New Risk Prediction Tool for Bleeding and Adverse Cardiovascular Events in Patients with Pre-Existing Coronary Stents Undergoing Gastrointestinal Cancer Surgery.Clinical interventions in aging · 2025Article
- Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?Nature reviews. Cardiology · 2024Review
- Prognostic Value of Quantitative Flow Ratio Combined with SYNTAX Scores I/II in Multivessel Coronary Artery Disease: A Small-Sample, Single-Center Study.Reviews in cardiovascular medicine · 2024Article
- Elucidating the Relationship between Neutrophil-Lymphocyte Ratio and Plaque Composition in Patients with Drug-Eluting Stent Restenosis by Virtual Histology-Intravascular Ultrasound.Journal of cardiovascular development and disease · 2024Article
Corrections and comments
- Commented on by
Authors and funding
33 authors at 20 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial. METHODS AND
resultsSYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CABG) or PCI, predicted by the SYNTAX score II. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which included any revascularization. The comparators were a matched PCI cohort trial and a matched CABG cohort, both from the SYNTAX I trial. At 5 years, MACCE rate in SYNTAX II was significantly lower than in the SYNTAX I PCI cohort (21.5% vs. 36.4%, P < 0.001). This reflected lower rates of revascularization (13.8% vs. 23.8%, P < 0.001), and myocardial infarction (MI) (2.7% vs. 10.4%, P < 0.001), consisting of both procedural MI (0.2% vs. 3.8%, P < 0.001) and spontaneous MI (2.3% vs. 6.9%, P = 0.004). All-cause mortality was lower in SYNTAX II (8.1% vs. 13.8%, P = 0.013) reflecting a lower rate of cardiac death (2.8% vs. 8.4%, P < 0.001). Major adverse cardiac and cerebrovascular events' outcomes at 5 years among patients in SYNTAX II and predefined patients in the SYNTAX I CABG cohort were similar (21.5% vs. 24.6%, P = 0.35).
conclusionsUse of the SYNTAX II PCI strategy in patients with de novo three-vessel disease led to improved and durable clinical results when compared to predefined patients treated with PCI in the original SYNTAX I trial. A predefined exploratory analysis found no significant difference in MACCE between SYNTAX II PCI and matched SYNTAX I CABG patients at 5-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.